Insightful Word
  • Investing
  • Stock
  • Economy
  • Politics
  • Investing
  • Stock
  • Economy
  • Politics
No Result
View All Result
Insightful Word
No Result
View All Result
Home Stock

Morgan Stanley upgrades Vir Biotechnology to ‘overweight,’ raises PT to $20

admin by admin
January 9, 2025
in Stock
0
Morgan Stanley upgrades Vir Biotechnology to ‘overweight,’ raises PT to $20
0
SHARES
2
VIEWS
Share on FacebookShare on Twitter

Investing.com — Morgan Stanley (NYSE:MS) analysts have upgraded Vir Biotechnology (NASDAQ:VIR) to an “overweight” rating, shifting from “equal-weight,” and have also increased their price target to $20 from $10. 

The analysts flagged promising preliminary data from the company’s dual-masked TCE therapies. Vir-5500, targeting prostate-specific membrane antigen in metastatic castration-resistant prostate cancer, demonstrated notable safety and efficacy in early trials. 

Among heavily pretreated participants, a 58% PSA50 response rate was observed, signaling a reduction in prostate-specific antigen levels. 

Another candidate, Vir-5818, showed early signs of efficacy in colorectal cancers, with partial tumor shrinkage in 33% of the treated cases. Both drugs exhibited manageable safety profiles, with no high-grade toxicities reported.

As per Morgan Stanley, the dual-masking technology offered by Vir can enhance therapeutic tolerability and efficacy, making these treatments more acceptable to earlier stages of cancer treatment. 

Additionally, the analysts noted that the company has extended its cash runway to mid-2027, enhancing its ability to fund ongoing clinical trials and explore strategic partnerships.

This upgrade comes as Vir diversifies beyond its traditional infectious disease portfolio into oncology. 

While the company has deprioritized some programs, such as hepatitis B, the focus on innovative cancer treatments aligns with its focus on high-potential areas. 

This post appeared first on investing.com

Previous Post

Saudi Arabia stocks higher at close of trade; Tadawul All Share up 0.07%

Next Post

Mexico inflation drops to 4.21%, approaching four-year record low

admin

admin

Next Post
Mexico inflation drops to 4.21%, approaching four-year record low

Mexico inflation drops to 4.21%, approaching four-year record low

Trending News

S&P 500 to continue grinding higher amid low Q3 earnings expectations: HSBC

S&P 500 to continue grinding higher amid low Q3 earnings expectations: HSBC

October 16, 2024
Coursera stock price analysis: will this edtech giant rebound?

Coursera stock price analysis: will this edtech giant rebound?

December 22, 2024
Should you invest in German stocks after the 2025 elections?

Should you invest in German stocks after the 2025 elections?

February 24, 2025
Subscribe to Insightful Word


    Recent News

    ARB eyes recovery as Arbitrum taps agentic DeFi revolution with $1M grant

    ARB eyes recovery as Arbitrum taps agentic DeFi revolution with $1M grant

    June 5, 2025
    Ripple releases $2.18B in XRP, price dips 2%

    Ripple releases $2.18B in XRP, price dips 2%

    June 5, 2025
    Nintendo Switch 2 launch sees shortages as 2.2M vie for units in Japan

    Nintendo Switch 2 launch sees shortages as 2.2M vie for units in Japan

    June 5, 2025
    Why Bank of America sees 13% upside on Roblox (RBLX)

    Why Bank of America sees 13% upside on Roblox (RBLX)

    June 5, 2025

    Recent News

    ARB eyes recovery as Arbitrum taps agentic DeFi revolution with $1M grant

    ARB eyes recovery as Arbitrum taps agentic DeFi revolution with $1M grant

    June 5, 2025
    Ripple releases $2.18B in XRP, price dips 2%

    Ripple releases $2.18B in XRP, price dips 2%

    June 5, 2025

    Latest News

    • ARB eyes recovery as Arbitrum taps agentic DeFi revolution with $1M grant
    • Ripple releases $2.18B in XRP, price dips 2%
    • Nintendo Switch 2 launch sees shortages as 2.2M vie for units in Japan

    About Insightful Word

    • Contacts
    • Cookie Notice
    • Privacy Policy
    • Terms of Service
    • Trading tools
    • Contacts
    • Cookie Notice
    • Privacy Policy
    • Terms of Service
    • Trading tools

    Copyright © 2025 Insightfulword.com. All Rights Reserved.

    No Result
    View All Result
    • Investing
    • Stock
    • Economy
    • Politics

    Copyright © 2025 Insightfulword.com. All Rights Reserved.